Basic Information
InflaRx is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent, and specific C5a inhibitors. Complement C5a is a powerful inflammatory mediator involved in the progression of various autoimmune and other inflammatory diseases. Our primary focus is on developing monoclonal antibodies targeting activated products of the complement system for application in life-threatening inflammatory diseases. We are a team of internationally recognized researchers and clinicians dedicated to translating discoveries and expertise into new therapeutic concepts for clinical applications.